Seminar & Colloquium
[콜로퀴엄: 3월 29일(수), 오후 5시] 한국과학기술연구원 (KIST), 권익찬 책임연구원
분자영상기술을 이용한 약물전달시스템의 설계
(Design of drug delivery guided by molecular imaging technology)
한국과학기술연구원 (KIST), 권익찬 책임연구원
Dr. Ick Chan Kwon is a Tenured Principal Research Scientist of Korea Institute of Science and Technology (KIST), Dean of KU-KIST Graduate School, Korea University as well as Affiliated Professor in Dept. of Bioengineering, University of Washington Seattle. He is currently a Presidential Scholar at KIST-DFCI On-Site-Lab in Dept. of Cancer Biology, Dana Farber Cancer Institute at Boston. He received his B.S. and M.S. degrees in Dept. of Textile Engineering, Seoul National University and his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from Univ. of Utah. After a post-doctoral training at Center for Controlled Chemical Delivery in Univ. of Utah, he joined KIST where he started his research on polymeric nanoparticle-based drug delivery system for antibiotics, anticancer drugs, and gene therapy. He also pioneered in research filed of Theragnosis, by combining molecular imaging and drug delivery system with smart nano-probes. He served as a president of the Korean Society of Molecular Imaging and served as an Editor for Asia of the Journal of Controlled Release (Elsevier). He is a fellow of The Korean Academy of Science & Technology and a senior member of The National Academy of Engineering of Korea.
| Date | Wednesday, March 29th, 2023
| Time | 17:00 ~
| Venue | #201, Bldg. 43-1 (43-1동 201호)
온라인 줌 링크 (https://snu-ac-kr.zoom.us/j/7952699081)**
회의 ID: 795 269 9081
** 줌링크는 외부 교수님들과 코로나로 인해 들어오지 못하는 학생들을 위한 줌 주소입니다. 재료콜로퀴엄 수강생들은 대면으로 참석하셔야합니다.
For decades, molecular imaging, capable of monitoring intercellular/intracellular molecular processes in organisms, has provided valuable information for a variety of research fields. Biomarkers such as enzymes, receptors, and proteins can provide information for early diagnosis of diseases and monitoring of therapeutic effects, and thus can be used as targets for molecular imaging. Among them, molecular imaging technology based on receptor-ligand interaction is emerging as a promising strategy for monitoring intractable diseases such as cancer. However, the basic requirement for this kind of imaging probe is to provide disease-specific information along with high imaging sensitivity. Here, we developed a self-quenching imaging probe capable of emitting fluorescence (activation) via a de-quenching reaction after internalization via receptor-ligand binding. Demonstrations of EGFR or CD47 target specific fluorescence signals will be presented in this presentation.
1. Y.J. Ko, et al, J. Controlled Release, 323, 376-386 (2020)
2. H.Y. Kim, et al, J. Controlled Release, 328, 222-236 (2020)
3. Y.J. Ko, et al, J. Controlled Release, 305, 1-17 (2019)
| Host | Prof. Woong-Ryeol Yu (880-9096)